is the tirzepatide shortage over FDA Says Compounded Must Exit Market Lilly CEO says weight-loss drug

Semaglutide : A potent GLP-1 receptor agonist that works by slowing digestion, reducing hunger, and promoting satiety, leading to less food intake

Glucagon receptor activation promotes: Increased thermogenesis (heat production) Enhanced fatty acid oxidation Mobilisation of stored lipids Increased resting energy expenditure In preclinical and clinical observations, this component allows retatrutide to increase the number of calories burned at rest not just reduce calories consumed

(That was the reason I chose Saturday for my injection dayto give me a day to recover from any ill effects)

Nutritional interventions leading to 5% weight loss are estimated to decrease LDL-C and non-HDL by 5%

The benefit/risk tool uses a traffic light system to help gauge risk and potential benefits in prescribing GLP-1 RAs, highlighting the various types of patients or clinical situations that are likely to be seen in a primary care setting: Low risk (green): robust evidence supports GLP-1 RA prescribing in these situations